Trial Profile
A Multicenter, Randomized, Parallel Group, Double Blind, Multiple Dose, Placebo Controlled Study to Assess the Efficacy and Safety of MNK-1411 in Male Participants 4 to 8 Years of Age With Duchenne Muscular Dystrophy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Tetracosactide (Primary) ; Tetracosactide (Primary)
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- Acronyms BRAVE
- Sponsors Mallinckrodt Inc.; Mallinckrodt plc
- 19 Jan 2020 According to EudraCT database this trial has been discontinued in spain
- 17 Jan 2020 This trial is Discontinued in Bulgaria,according to European Clinical Trials Database record.
- 16 Jan 2020 Planned End Date changed from 1 Aug 2020 to 1 Feb 2020.